BRIEF-GlaxoSmithkline Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma
Visit Now - http://zeroviral.com/brief-glaxosmithkline-announces-chmp-positive-opinion-for-labelling-update-to-relvar-ellipta-in-patients-with-asthma/
BRIEF-GlaxoSmithkline Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma
Jan 26 (Reuters) – GlaxoSmithkline Plc:
* GSK‘S RELVAR ELLIPTA – POSITIVE CHMP OPINION
* GSK ANNOUNCES CHMP POSITIVE OPINION FOR LABELLING UPDATE TO RELVAR ELLIPTA IN PATIENTS WITH ASTHMA
* NO NEW SAFETY SIGNALS WERE IDENTIFIED AND ADVERSE EVENT DATA WERE CONSISTENT WITH KNOWN SAFETY PROFILE FOR FF/VI ESTABLISHED IN PATIENTS WITH ASTHMA
* FINAL DECISION IS ANTICIPATED TOWARDS END OF Q1 OF 2018 Source textual content for Eikon: Further firm protection: ([email protected])
Our Standards:The Thomson Reuters Trust Principles.
